December 15th, 2015

Company Update (NASDAQ:BIIB): Biogen Idec and Sobi Announce European Medicines Agency Validates ELOCTA™ (rFVIIIFc) Marketing Authorization Application for Review

[Business Wire] – CAMBRIDGE, Mass. & STOCKHOLM–(BUSINESSWIRE)– Biogen Idec (NASDAQ:BIIB – News) and Swedish Orphan Biovitrum AB (publ) (Sobi) (STO:SOBI.ST – News) today announced that the European Medicines Agency (EMA) has validated the . . . → Read More: Company Update (NASDAQ:BIIB): Biogen Idec and Sobi Announce European Medicines Agency Validates ELOCTA™ (rFVIIIFc) Marketing Authorization Application for Review Similar Articles: Stock Update (NYSE:BMY): UPDATE 1-Bristol-Myers pulls U.S. marketing application for hepatitis C treatment Market Update: Biogen Idec Inc (NASDAQ:BIIB) – Detailed Results from Biogen Idec and AbbVie’s Pivotal Phase 3 Decide Study Further Define the Efficacy and Safety Profile of ZINBRYTA™ (Daclizumab High-Yield Process) Company Update: Biogen Idec Inc (NASDAQ:BIIB) – Donald Johns Joins Biogen Idec to Lead ALS Innovation Hub
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.